Cardiff Oncology (CRDF) News Today $2.82 +0.11 (+4.06%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.81 -0.01 (-0.35%) As of 05/2/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Acorn Capital Advisors LLC Acquires New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF)Acorn Capital Advisors LLC acquired a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,442,308 shares of the company's stock, valued at approximMay 4 at 7:21 AM | marketbeat.comBoothbay Fund Management LLC Purchases Shares of 129,960 Cardiff Oncology, Inc. (NASDAQ:CRDF)Boothbay Fund Management LLC purchased a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 129,960 shares of the company's stock, valuMay 3 at 5:08 AM | marketbeat.comCardiff Oncology: Expecting Massive Updates In Colon Cancer SoonMay 2 at 4:03 AM | seekingalpha.com1,292,308 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Purchased by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. bought a new position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,292,308 shares of the company's stock, valued at approxMay 1 at 5:30 AM | marketbeat.comRenaissance Technologies LLC Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)Renaissance Technologies LLC trimmed its holdings in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 483,090 shares of thApril 28, 2025 | marketbeat.comCardiff Oncology (CRDF) to Release Earnings on ThursdayCardiff Oncology (NASDAQ:CRDF) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-cardiff-oncology-inc-stock/)April 26, 2025 | marketbeat.comCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsApril 23, 2025 | globenewswire.comCardiff Oncology completes patient enrollment in CRDF-004 trialApril 16, 2025 | markets.businessinsider.comCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 15, 2025 | globenewswire.comCardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal CancerApril 15, 2025 | globenewswire.comCardiff Oncology (CRDF) Receives a Buy from Piper SandlerApril 14, 2025 | markets.businessinsider.comCardiff Oncology initiated with a Buy at Lucid CapitalApril 4, 2025 | markets.businessinsider.comBank of New York Mellon Corp Increases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF)Bank of New York Mellon Corp grew its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 68.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 288,615 shares of the company's stock after purchaMarch 24, 2025 | marketbeat.comQ1 Earnings Forecast for CRDF Issued By William BlairCardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a report issued on Thursday, February 27th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.26)March 3, 2025 | marketbeat.comEarnings call transcript: Cardiff Oncology Q4 2024 highlights strategic advancesMarch 1, 2025 | uk.investing.comCardiff Oncology Reports Positive Initial Efficacy Data for Onvansertib in Metastatic Colorectal Cancer and Secures $40 Million FinancingMarch 1, 2025 | nasdaq.comHC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) StockHC Wainwright increased their target price on shares of Cardiff Oncology from $13.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday.March 1, 2025 | marketbeat.comCardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings ResultsCardiff Oncology (NASDAQ:CRDF - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%.February 28, 2025 | marketbeat.comCardiff Oncology price target raised to $17 from $13 at H.C. WainwrightFebruary 28, 2025 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)February 28, 2025 | markets.businessinsider.comCardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comCardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comCardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateFebruary 27, 2025 | globenewswire.comCardiff Oncology to Present at Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comWilliam Blair Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)February 20, 2025 | markets.businessinsider.comCardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business UpdateFebruary 20, 2025 | globenewswire.comBullish Cardiff Oncology Insiders Rewarded As Their Investment Rises To US$1.81mFebruary 20, 2025 | finance.yahoo.comCardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With OnvansertibFebruary 18, 2025 | seekingalpha.comCardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest UpdateCardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 10,450,000 shares, a growth of 10.2% from the January 15th total of 9,480,000 shares. Based on an average trading volume of 2,070,000 shares, the short-interest ratio is currently 5.0 days.February 16, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 203,292 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)Assenagon Asset Management S.A. cut its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 75.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,231 shares of the company's stock afJanuary 26, 2025 | marketbeat.comShort Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 21.6%Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 9,950,000 shares, a growth of 21.6% from the November 30th total of 8,180,000 shares. Based on an average trading volume of 1,900,000 shares, the days-to-cover ratio is presently 5.2 days.December 31, 2024 | marketbeat.comWhile institutions own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), retail investors are its largest shareholders with 57% ownershipDecember 23, 2024 | finance.yahoo.comCraig-Hallum Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)December 17, 2024 | markets.businessinsider.comShort Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 6.0%Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 8,180,000 shares, a growth of 6.0% from the November 15th total of 7,720,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the days-to-cover ratio is presently 5.5 days.December 16, 2024 | marketbeat.comTD Cowen Keeps Their Buy Rating on Cardiff Oncology (CRDF)December 14, 2024 | markets.businessinsider.comCardiff Oncology (NASDAQ:CRDF) Price Target Raised to $10.00 at Piper SandlerPiper Sandler raised their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an "overweight" rating in a report on Friday.December 13, 2024 | marketbeat.comInsider Buying: Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Buys 350,115 Shares of StockDecember 13, 2024 | insidertrades.comCardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just BeginningDecember 12, 2024 | seekingalpha.comCardiff Oncology (CRDF) Gets a Buy from Craig-HallumDecember 11, 2024 | markets.businessinsider.comCardiff Oncology Reports Promising Phase 2 Trial ResultsDecember 11, 2024 | finance.yahoo.comCardiff Oncology (NASDAQ:CRDF) Stock, Short Interest ReportDecember 11, 2024 | benzinga.comCardiff Oncology prices $40M registered direct offering at $2.60 per shareDecember 11, 2024 | markets.businessinsider.comCardiff Oncology (NASDAQ:CRDF) Stock Quotes, Forecast and News SummaryDecember 11, 2024 | benzinga.comCardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal CancerDecember 10, 2024 | seekingalpha.comCardiff Oncology Shares Rise 45% On Initial Positive Results in Colon Cancer TrialDecember 10, 2024 | marketwatch.comCardiff Oncology Prices About $40 Mln Oversubscribed Offering To Fund Colorectal Cancer TrialsDecember 10, 2024 | markets.businessinsider.comCardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical TrialDecember 10, 2024 | globenewswire.comCardiff Oncology announces new patent with claims for onvansertibNovember 19, 2024 | markets.businessinsider.comCardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRCNovember 19, 2024 | markets.businessinsider.comCardiff Oncology price target lowered to $13 from $14 at H.C. WainwrightNovember 9, 2024 | markets.businessinsider.com Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Media Mentions By Week CRDF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDF News Sentiment▼1.120.73▲Average Medical News Sentiment CRDF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDF Articles This Week▼51▲CRDF Articles Average Week Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DAWN News Today OCS News Today CVAC News Today ABCL News Today RCKT News Today ZYME News Today QURE News Today XNCR News Today LENZ News Today PAHC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDF) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRDF Stock Free CRDF Stock Alerts